Cargando…
Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2
The complex immune tumour microenvironment requires an equally complex immunotherapy approach, especially when the cancer-immune set point is non-inflamed. Oncolytic viruses expressing immune activating cytokines might optimally modify the immune microenvironment and improve the antitumour effects....
Autores principales: | Liu, Zuqiang, Ge, Yan, Wang, Haiyan, Ma, Congrong, Feist, Mathilde, Ju, Songguang, Guo, Z. Sheng, Bartlett, David L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224581/ https://www.ncbi.nlm.nih.gov/pubmed/30410056 http://dx.doi.org/10.1038/s41467-018-06954-z |
Ejemplares similares
-
Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation
por: Chen, Lingjuan, et al.
Publicado: (2021) -
Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety
por: Ge, Yan, et al.
Publicado: (2020) -
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
por: Guo, Zong Sheng, et al.
Publicado: (2019) -
In Vivo Priming of Peritoneal Tumor-Reactive Lymphocytes With a Potent Oncolytic Virus for Adoptive Cell Therapy
por: Giehl, Esther, et al.
Publicado: (2021) -
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
por: Liu, Zuqiang, et al.
Publicado: (2017)